---
title: "Bambusa Therapeutics climbs 3% to 52-week high"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305036908.md"
description: "Bambusa Therapeutics rose 3.31% to $17.49 during regular trading, hitting a 52-week high intraday."
datetime: "2026-11-10T15:27:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305036908.md)
  - [en](https://longbridge.com/en/news/305036908.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305036908.md)
generator: "portal-rs"
---

# Bambusa Therapeutics climbs 3% to 52-week high

Bambusa Therapeutics (BBTX.US) climbed more than **3%** during regular trading to **$17.49**, hitting a 52-week high intraday.

Peter Kolchinsky and Rajeev Shah disclosed on Nov. 6 that they hold a **14.6%** stake in the company. On the same day, Bambusa completed an oversubscribed initial public offering at **$16** per share, raising **$169 million**.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [BBTX.US](https://longbridge.com/en/quote/BBTX.US.md)

## Related News & Research

- [Peter Kolchinsky and Rajeev Shah Disclose 14.6% Stake in Bambusa Therapeutics](https://longbridge.com/en/news/304691682.md)
- [Bambusa Therapeutics Director Helmut Wolfgang Jeggle Reports $6 Million Common Share Acquisition](https://longbridge.com/en/news/304008064.md)
- [BUZZ-Street View: Nvidia's AI story intact despite uncertainty at top](https://longbridge.com/en/news/305945171.md)
- [Will Upper Stage Recovery Change SpaceX's (SPCX) Narrative](https://longbridge.com/en/news/305914563.md)
- [Will Revenue Outlook Cut Change Lululemon Stock's Narrative](https://longbridge.com/en/news/305993397.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**